NO971566L - Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF - Google Patents

Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF

Info

Publication number: NO971566L
Authority: NO; Norway
Prior art keywords: kgf; diabetes mellitus; treating diabetes; mammals; diabetes
Prior art date: 1994-10-13

Application number

NO971566A

Other languages

English (en)

Norwegian (no)

Other versions

NO971566D0 (no

Inventor

Sharon Lea Aukerman

Glenn Francis Pierce

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-10-13

Filing date

1997-04-04

Publication date

1997-04-14

1997-04-04 Application filed by Amgen Inc filed Critical Amgen Inc

1997-04-04 Publication of NO971566D0 publication Critical patent/NO971566D0/no

1997-04-14 Publication of NO971566L publication Critical patent/NO971566L/no

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/50—Fibroblast growth factor [FGF]

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Diabetes (AREA)
Gastroenterology & Hepatology (AREA)
Endocrinology (AREA)
Immunology (AREA)
Hematology (AREA)
Obesity (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Emergency Medicine (AREA)
Zoology (AREA)
Pain & Pain Management (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO971566A 1994-10-13 1997-04-04 Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF NO971566L (no)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US32347594A	1994-10-13	1994-10-13
US32334094A	1994-10-13	1994-10-13
US48782595A	1995-06-07	1995-06-07
PCT/IB1995/000992 WO1996011950A1 (en)	1994-10-13	1995-10-12	Method of treating diabetes mellitus using kgf

Publications (2)

Publication Number	Publication Date
NO971566D0 NO971566D0 (no)	1997-04-04
NO971566L true NO971566L (no)	1997-04-14

Family

ID=27406268

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO971566A NO971566L (no)	1994-10-13	1997-04-04	Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF
NO19971568A NO318761B1 (no)	1994-10-13	1997-04-04	Polypeptidanalog til nativ keratinocyttvekstfaktor kalt "KGF", farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitelceller samt sett.

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
NO19971568A NO318761B1 (no)	1994-10-13	1997-04-04	Polypeptidanalog til nativ keratinocyttvekstfaktor kalt "KGF", farmasoytisk formulering, rekombinant nukleinsyremolekyl, biologisk funksjonell vektor, prokaryot eller eukaryot vertscelle, fremgangsmate for fremstilling av en analog av KGF, anvendelse av en effektiv mengde av analogen av KGF i folge oppfinnelsen, eller deltaN23 for fremstilling av et medikament for stimulering av produksjon av ikke-fibroblastepitelceller, in vitro fremgangsmate for stimulering av produksjon av ikke-fibroblastepitelceller samt sett.

Country Status (23)

Country	Link
EP (2)	EP0785948B1 (de)
JP (2)	JP4216329B2 (de)
KR (1)	KR100278597B1 (de)
CN (1)	CN1168678A (de)
AT (2)	ATE342278T1 (de)
AU (1)	AU3707795A (de)
BG (2)	BG101392A (de)
BR (2)	BR9509269A (de)
CA (2)	CA2202075C (de)
CZ (3)	CZ297329B6 (de)
DE (2)	DE69530403T2 (de)
DK (2)	DK0804479T3 (de)
EE (2)	EE03975B1 (de)
ES (2)	ES2196082T3 (de)
FI (2)	FI971420A0 (de)
HU (2)	HUT78050A (de)
NO (2)	NO971566L (de)
NZ (2)	NZ505502A (de)
PL (2)	PL182888B1 (de)
PT (2)	PT785948E (de)
SI (2)	SI0785948T1 (de)
SK (2)	SK284534B6 (de)
WO (2)	WO1996011949A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2153816T3 (es)	1989-01-31	2001-03-16	Jeffrey S Rubin	Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
US7084119B2 (en)	1993-06-29	2006-08-01	Chiron Corporation	Truncated keratinocyte growth factor (KGF) having increased biological activity
KR960703433A (ko)	1993-06-29	1996-08-17	로버트 피. 블랙버언	증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity)
IL115605A (en) *	1994-10-13	2003-06-24	Amgen Inc	Method for purifying keratinocyte growth factors
US7232667B2 (en)	1995-02-14	2007-06-19	Human Genome Sciences, Inc.	Keratinocyte growth factor-2 polynucleotides
US6693077B1 (en)	1995-02-14	2004-02-17	Human Genome Sciences, Inc.	Keratinocyte growth factor-2
US6077692A (en)	1995-02-14	2000-06-20	Human Genome Sciences, Inc.	Keratinocyte growth factor-2
DE69603269T3 (de) *	1995-04-27	2007-02-22	Coöperatie Cosun U.A.	Derivate von inulin
US6743422B1 (en)	1996-10-15	2004-06-01	Amgen, Inc.	Keratinocyte growth factor-2 products
DK0935652T3 (da) *	1996-10-15	2004-07-26	Amgen Inc	Keratinocyt vækstfaktor-2 produkter
EP1473366A1 (de) *	1996-10-15	2004-11-03	Amgen Inc.	Produkte des Keratinocyten-Wachstumsfaktors 2
US7495087B2 (en)	1997-07-14	2009-02-24	Bolder Biotechnology, Inc.	Cysteine muteins in the C-D loop of human interleukin-11
US7153943B2 (en)	1997-07-14	2006-12-26	Bolder Biotechnology, Inc.	Derivatives of growth hormone and related proteins, and methods of use thereof
US20080076706A1 (en)	1997-07-14	2008-03-27	Bolder Biotechnology, Inc.	Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
ATE375363T1 (de)	1997-07-14	2007-10-15	Bolder Biotechnology Inc	Derivate des wachstumshormons und verwandte proteine
US6869927B1 (en)	1997-12-22	2005-03-22	Human Genome Sciences, Inc.	Keratinocyte growth factor-2 formulations
WO1999032135A1 (en)	1997-12-22	1999-07-01	Human Genome Sciences, Inc.	Keratinocyte growth factor-2 formulations
US6242666B1 (en) *	1998-12-16	2001-06-05	The Scripps Research Institute	Animal model for identifying a common stem/progenitor to liver cells and pancreatic cells
US8288126B2 (en)	1999-01-14	2012-10-16	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
BR122013003013B8 (pt) *	1999-01-14	2021-07-06	Bolder Biotechnology Inc	proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
US6248725B1 (en)	1999-02-23	2001-06-19	Amgen, Inc.	Combinations and methods for promoting in vivo liver cell proliferation and enhancing in vivo liver-directed gene transduction
CA2437270A1 (en) *	2001-02-06	2002-08-15	Merck Patent Gesellschaft Mit Beschraenkter Haftung	Modified keratinocyte growth factor (kgf) with reduced immunogenicity
JP2005500390A (ja)	2001-08-21	2005-01-06	カイロンコーポレイション	Ｋｇｆポリペプチド組成物
AU2007214362B2 (en) *	2001-08-21	2009-11-26	Novartis Vaccines And Diagnostics, Inc.	KGF polypeptide compositions
US8304387B2 (en)	2004-12-15	2012-11-06	Swedish Orphan Biovitrum Ab (Publ)	Therapeutic formulations of keratinocyte growth factor
CN102242124B (zh) *	2010-05-10	2013-05-22	齐鲁制药有限公司	改造的角化细胞生长因子基因及其在酵母中的表达
KR102440312B1 (ko) *	2020-08-28	2022-09-05	한국해양과학기술원	온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
JPH01137994A (ja) *	1987-08-10	1989-05-30	Shionogi & Co Ltd	ｒｅｇ蛋白質
US5145225A (en) *	1988-07-27	1992-09-08	Muller George M	Carpet stretcher
ES2153816T3 (es) *	1989-01-31	2001-03-16	Jeffrey S Rubin	Adn que codifica un factor de crecimiento especifico contra celulas epiteliales.
JP3303211B2 (ja) *	1991-04-26	2002-07-15	武田薬品工業株式会社	ｂＦＧＦムテインおよびその製造法
JP3578761B2 (ja) *	1993-03-26	2004-10-20	アムジエン・インコーポレーテツド	表皮ケラチン細胞成長因子の治療目的での使用
US5348563A (en) *	1993-06-29	1994-09-20	Honeywell Inc.	Air purifying apparatus
KR960703433A (ko) *	1993-06-29	1996-08-17	로버트 피. 블랙버언	증가된 생물학적 활성을 갖는 끝이 잘린 케라틴세포성장인자(kgf) (a truncated keratinocyte growth factor(kgf) having increased biological activity)
GB9315501D0 (en) *	1993-07-27	1993-09-08	Ici Plc	Surfactant compositions
AU7475694A (en) *	1993-08-02	1995-02-28	Prizm Pharmaceuticals, Inc.	Monogenous preparations of cytotoxic conjugates

1995
- 1995-10-12 DE DE69530403T patent/DE69530403T2/de not_active Expired - Lifetime
- 1995-10-12 DE DE69535264T patent/DE69535264T2/de not_active Expired - Lifetime
- 1995-10-12 SK SK455-97A patent/SK284534B6/sk not_active IP Right Cessation
- 1995-10-12 PL PL95319784A patent/PL182888B1/pl not_active IP Right Cessation
- 1995-10-12 EE EE9700081A patent/EE03975B1/xx not_active IP Right Cessation
- 1995-10-12 ES ES95934793T patent/ES2196082T3/es not_active Expired - Lifetime
- 1995-10-12 NZ NZ505502A patent/NZ505502A/en not_active IP Right Cessation
- 1995-10-12 SI SI9530654T patent/SI0785948T1/xx unknown
- 1995-10-12 CZ CZ20023953A patent/CZ297329B6/cs not_active IP Right Cessation
- 1995-10-12 BR BR9509269A patent/BR9509269A/pt not_active Application Discontinuation
- 1995-10-12 FI FI971420A patent/FI971420A0/fi unknown
- 1995-10-12 CZ CZ0105097A patent/CZ297328B6/cs not_active IP Right Cessation
- 1995-10-12 SI SI9530728T patent/SI0804479T1/sl unknown
- 1995-10-12 JP JP51307796A patent/JP4216329B2/ja not_active Expired - Fee Related
- 1995-10-12 HU HU9901071A patent/HUT78050A/hu unknown
- 1995-10-12 AT AT95934808T patent/ATE342278T1/de active
- 1995-10-12 PT PT95934793T patent/PT785948E/pt unknown
- 1995-10-12 PT PT95934808T patent/PT804479E/pt unknown
- 1995-10-12 EP EP95934793A patent/EP0785948B1/de not_active Expired - Lifetime
- 1995-10-12 DK DK95934808T patent/DK0804479T3/da active
- 1995-10-12 DK DK95934793T patent/DK0785948T3/da active
- 1995-10-12 EP EP95934808A patent/EP0804479B1/de not_active Expired - Lifetime
- 1995-10-12 SK SK431-97A patent/SK43197A3/sk unknown
- 1995-10-12 AT AT95934793T patent/ATE237633T1/de active
- 1995-10-12 KR KR1019970702343A patent/KR100278597B1/ko not_active Expired - Fee Related
- 1995-10-12 CN CN95196410A patent/CN1168678A/zh active Pending
- 1995-10-12 AU AU37077/95A patent/AU3707795A/en not_active Abandoned
- 1995-10-12 PL PL95320484A patent/PL320484A1/xx unknown
- 1995-10-12 WO PCT/IB1995/000971 patent/WO1996011949A2/en not_active Ceased
- 1995-10-12 WO PCT/IB1995/000992 patent/WO1996011950A1/en not_active Ceased
- 1995-10-12 ES ES95934808T patent/ES2273338T3/es not_active Expired - Lifetime
- 1995-10-12 HU HU9901255A patent/HU226168B1/hu not_active IP Right Cessation
- 1995-10-12 EE EE9700225A patent/EE9700225A/xx unknown
- 1995-10-12 CA CA002202075A patent/CA2202075C/en not_active Expired - Fee Related
- 1995-10-12 CZ CZ97981A patent/CZ98197A3/cs unknown
- 1995-10-12 BR BR9509329A patent/BR9509329A/pt not_active Application Discontinuation
- 1995-10-12 JP JP51307696A patent/JP4426646B2/ja not_active Expired - Fee Related
- 1995-10-12 CA CA002201940A patent/CA2201940C/en not_active Expired - Fee Related
1997
- 1997-04-04 NO NO971566A patent/NO971566L/no unknown
- 1997-04-04 NO NO19971568A patent/NO318761B1/no not_active IP Right Cessation
- 1997-04-07 BG BG101392A patent/BG101392A/xx unknown
- 1997-04-11 FI FI971536A patent/FI120040B/fi not_active IP Right Cessation
- 1997-04-11 BG BG101408A patent/BG63167B1/bg unknown
1999
- 1999-04-09 NZ NZ335109A patent/NZ335109A/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
SK43197A3 (en)	1999-03-12
CA2201940C (en)	2009-05-12
PL182888B1 (pl)	2002-03-29
FI971420A7 (fi)	1997-04-04
NO971566D0 (no)	1997-04-04
SK45597A3 (en)	1999-02-11
EP0785948A1 (de)	1997-07-30
JP4216329B2 (ja)	2009-01-28
FI971536L (fi)	1997-06-09
WO1996011949A3 (en)	1996-12-12
BG63167B1 (bg)	2001-05-31
CZ297328B6 (cs)	2006-11-15
AU681546B2 (en)	1997-08-28
FI971536A0 (fi)	1997-04-11
AU3708395A (en)	1996-05-06
DE69535264T2 (de)	2007-02-01
JPH10507080A (ja)	1998-07-14
FI120040B (fi)	2009-06-15
BR9509269A (pt)	1997-12-23
BR9509329A (pt)	1997-10-14
SI0785948T1 (en)	2003-08-31
NZ335109A (en)	2000-08-25
CZ297329B6 (cs)	2006-11-15
FI971420L (fi)	1997-04-04
EE9700081A (et)	1997-10-15
HUT78058A (hu)	1999-07-28
ATE237633T1 (de)	2003-05-15
CZ98197A3 (cs)	1998-11-11
NO971568D0 (no)	1997-04-04
CA2202075C (en)	2003-12-09
KR100278597B1 (ko)	2001-01-15
EP0785948B1 (de)	2003-04-16
DK0804479T3 (da)	2007-01-29
DE69530403T2 (de)	2003-10-30
WO1996011949A2 (en)	1996-04-25
PL319784A1 (en)	1997-08-18
EP0804479A1 (de)	1997-11-05
ES2196082T3 (es)	2003-12-16
EE9700225A (et)	1998-02-16
DK0785948T3 (da)	2003-08-04
HUT78050A (hu)	1999-07-28
HU226168B1 (en)	2008-05-28
JP4426646B2 (ja)	2010-03-03
CA2202075A1 (en)	1996-04-25
BG101408A (bg)	1997-12-30
EP0804479B1 (de)	2006-10-11
WO1996011950A1 (en)	1996-04-25
JPH10507193A (ja)	1998-07-14
DE69535264D1 (de)	2006-11-23
AU3707795A (en)	1996-05-06
ATE342278T1 (de)	2006-11-15
EE03975B1 (et)	2003-02-17
PT785948E (pt)	2003-09-30
SK284534B6 (sk)	2005-06-02
NO971568L (no)	1997-06-12
NO318761B1 (no)	2005-05-02
PT804479E (pt)	2007-02-28
FI971420A0 (fi)	1997-04-04
BG101392A (en)	1997-10-31
SI0804479T1 (sl)	2006-12-31
CA2201940A1 (en)	1996-04-25
ES2273338T3 (es)	2007-05-01
CZ105097A3 (cs)	1998-10-14
PL320484A1 (en)	1997-09-29
NZ505502A (en)	2005-01-28
DE69530403D1 (de)	2003-05-22
CN1168678A (zh)	1997-12-24

Publication	Publication Date	Title
NO971566L (no)	1997-04-14	Fremgangsmåte for behandling av diabetes mellitus ved anvendelse av KGF
DE69027865D1 (de)	1996-08-22	ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
NO963785L (no)	1996-11-01	Fremgangsmåte for behandling av 5HT2B-reseptor-relaterte betingelser
AU5729098A (en)	1998-07-17	Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes
NO981810D0 (no)	1998-04-22	Sammensetninger og fremgangsmÕter for behandling av tilstander ved bensvikt
NO972451L (no)	1997-07-25	Heterosyklyloksy- og tiometyl-1,2,5-tiadiazolidin-3-on 1,1-dioksyder og preparater og fremgangsmåte for anvendelse derav
NO963322D0 (no)	1996-08-09	Fremgangsmåte for behandling av abstinens ved stoffmisbruk
SE9603725D0 (sv)	1996-10-11	New teatment
NO972449L (no)	1997-07-22	Substituerte 2-arylkarbonyloksymetyl-1,2,5-tiadiazolidin-3-on-1,1-dioksidderivater og preparater og fremgangsmåte for anvendelse derav
SE9600120D0 (sv)	1996-01-15	Novel medical use
DE69626816D1 (de)	2003-04-24	Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
EP0909172A4 (de)	1999-06-09	Verfahren und zusammensetzungen zur behandlung von harninkontinenz unter verwendung von enantiomer-angereichertem (r,s)-glycopyrrolat
DE69818809D1 (de)	2003-11-13	Verfahren zur behandlung von narbengewebe
NO963366D0 (no)	1996-08-13	Peptider og fremgangsmåte for behandling av diabetes
ATE306278T1 (de)	2005-10-15	Behandlung von knochenleiden mit adrenomedullin
DE69110861D1 (de)	1995-08-03	Mittel zur verbesserung des kollagenmetabolismus und dessen verwendung.
NO984198L (no)	1998-11-02	FremgangsmÕte for behandling av aggresjon
AUPM836794A0 (en)	1994-10-20	Improved method and composition for the treatment of ulcers
UA30448A (uk)	2000-11-15	Спосіб формування холедоходуоденоанастомозу
AU3597695A (en)	1996-04-09	Improved method and composition for the treatment of ulcers
AUPN733195A0 (en)	1996-01-25	Improved method and composition for the treatment of ulcers
IT1285551B1 (it)	1998-06-18	Composizione e procedimento per la sterilizzazione di substrati di coltura
AU6459996A (en)	1997-02-10	Composition and method for treating diabetes